REUTERS - Israel-based MediWound has signed a five-year, $112 million contract with the U.S. authority that handles public health medical emergencies to further develop and buy the company's drug treatment for severe burns.
- Four Chinese Groups in Race to Buy Clal Insurance From IDB Group
- MediWound Files for $80 millionIPO
- Sales of Two of Israel’s Biggest Insurers Advance
Investment group Clal Biotechnology, which has a 45 percent stake in MediWound, said in a statement that the deal with the Biomedical Advanced Research and Development Authority would raise preparedness for mass-casualty incidents.
The U.S. body would also help MediWound get approval for its drug NexoBrid, a topical treatment that removes damaged tissue, from the Food and Drug Administration, Clal said.
Clal's shares were up 18.6 percent in Tel Aviv in midday trading.